You are here

A Study of Avelumab in Combination With Axitinib In Non-Small Cell Lung Cancer (NSCLC) or Urothelial Cancer (Javelin Medley VEGF)

Last updated on November 13, 2019

FOR MORE INFORMATION
Study Location
Cardiologia Blocco A piano 5
Perugia, , 06129 Italy
Contact
1-800-718-1021
Eligibility criteria
Condition
The disease, disorder, syndrome, illness, or injury that is being studied.
Non-Small Cell Lung Cancer, Urothelial Cancer
Sex
Females and Males
Age
Pediatric Trials: 0-17 Years
Adult Trials: 18+ Years
18 + years
Inclusion criteria
The factors, or reasons, that allow a person to participate in a clinical study.
Show details

- Non-small cell lung cancer (NSCLC) Cohort: Histologically or cytologically confirmed
diagnosis of NSCLC that is locally advanced or metastatic; No activating EGFR
mutations, ALK or ROS1 translocations/rearrangements where testing is standard of
care; received at least 1 prior platinum‑based chemotherapy regimen for locally
advanced or metastatic NSCLC; No more than 2 prior lines of systemic therapy for
locally advanced or metastatic disease (If disease progression occurred during or
within 6 months after neoadjuvant/adjuvant chemotherapy or radiotherapy‑chemotherapy,
the regimen is counted as 1 prior treatment regimen towards the allowed limit of prior
treatment regimens); Checkpoint inhibitor naïve.

- Urothelial Cancer (UC) Cohort: Histologically or cytologically confirmed diagnosis of
transitional cell carcinoma (TCC) of the urothelium (if mixed, more than 50% TCC
component) including bladder, urethra, ureters, or renal pelvis that is locally
advanced or metastatic; No prior systemic treatment for locally advanced or metastatic
disease; Prior neoadjuvant or adjuvant therapy is permitted if disease progression
occurred >12 months after the completion of therapy; Checkpoint inhibitor naïve;
Ineligible for receiving cisplatin‑containing front‑line chemotherapy based at least
one of the following criteria: ECOG performance status (PS) 2; Renal dysfunction
(defined as creatinine‑clearance hearing loss (hearing loss measured by audiometry of 25 decibels at two contiguous
frequencies).

- At least 1 measurable lesion by RECIST v1.1 not previously irradiated.

- Availability of an archival FFPE tumor tissue block from primary diagnosis specimen or
metastatic specimen or 15 unstained slides (10 minimum). If an archived sample is not
available, a fresh tumor biopsy must be performed.

- Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1. For UC
patients, ECOG performance 2 is permitted (cisplatin ineligibility criterion)

Exclusion criteria
The factors, or reasons, that prevent a person from participating in a clinical study.
Show details

- Prior immunotherapy with an anti?PD?1, anti?PD?L1, anti?PD?L2, anti?CD137, anti?OX?40,
anti?GITR, anti?LAG?3, anti?TIM?3 or anti?CTLA?4 antibody (including ipilimumab).

- Newly diagnosed brain metastases or known symptomatic brain metastases requiring
steroids.

- Radiologically documented evidence of major blood vessel invasion or encasement by
cancer or intratumor cavitation, regardless of tumor histology.

- Active autoimmune disease (that might deteriorate when receiving an immunostimulatory
agent).

- Current use of immunosuppressive medication (except for those listed in protocol).

- Known prior severe hypersensitivity to the investigational products /monoclonal
antibodies.

- Known history of immune?mediated colitis, inflammatory bowel disease, immune?mediated
pneumonitis, pulmonary fibrosis.

- NCI CTCAE Grade 3 hemorrhage within 28 days prior to study enrollment.

NCT03472560
Pfizer
Not yet recruiting
A Study of Avelumab in Combination With Axitinib In Non-Small Cell Lung Cancer (NSCLC) or Urothelial Cancer (Javelin Medley VEGF)

NEED INFO?

Questions about a trial? Call or email to reach a Pfizer Clinical Trial Contact Center Representative

Pfizer Clinical Trials Contact Center

1-800-718-1021

[email protected]

call now

Try a new search

Search for Clinical Trials by condition, keyword or trial number. Share your location or enter your city or zip code to find studies near you.

Based on your search, you may also be interested in

Non-Small Cell Lung Cancer, Triple-negative Breast Cancer
NCT03674827
All Genders
18+
Years
Multiple Sites
Squamous Cell Carcinoma of the Head and Neck, Renal Cell Carcinoma, Ovarian Cancer, Gastric Cancer, Esophageal Cancer, Lung Squamous Cell Carcinoma, Pancreatic Cancer, Bile Duct Cancer, Endometrial Cancer, Melanoma Cancer, Urothelial Cancer
NCT04152018
All Genders
18+
Years
San Antonio, Texas
Non-Small Cell Lung Cancer
NCT02349633
All Genders
18+
Years
Multiple Sites
Descriptive Information
Brief Title  ICMJE A Study of Avelumab in Combination With Axitinib In Non-Small Cell Lung Cancer (NSCLC) or Urothelial Cancer (Javelin Medley VEGF)
Official Title  ICMJE A PHASE 2, OPEN LABEL STUDY TO EVALUATE SAFETY AND CLINICAL ACTIVITY OF AVELUMAB (BAVENCIO (REGISTERED)) IN COMBINATION WITH AXITINIB (INLYTA (REGISTERED)) IN PATIENTS WITH ADVANCED OR METASTATIC PREVIOUSLY TREATED NON-SMALL CELL LUNG CANCER OR TREATMENT NAÏVE CISPLATIN-INELIGIBLE UROTHELIAL CANCER JAVELIN MEDLEY VEGF
Brief SummaryThis is a Phase 2 study to evaluate the safety and efficacy of avelumab in combination with axitinib in patients with advanced or metastatic non-small cell lung cancer (NSCLC) who have received at least one prior platinum containing therapy, and in treatment naïve patients with advanced or metastatic urothelial cancer, who are ineligible for cisplatin containing chemotherapy for their advanced disease.
Detailed DescriptionNot Provided
Study Type  ICMJE Interventional
Study Phase  ICMJE Phase 2
Study Design  ICMJE Intervention Model: Single Group Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Condition  ICMJE
  • Non-Small Cell Lung Cancer
  • Urothelial Cancer
Intervention  ICMJE
  • Drug: Avelumab (MSB0010718C)
    IV treatment: Avelumab administered at 800 mg IV every two weeks
    Other Name: Bavencio
  • Drug: Axitinib (AG-013736)
    Oral treatment: Axitinib given 5 mg PO BID
    Other Name: Inlyta
Study Arms  ICMJE Experimental: Avelumab in combination with axitinib
Avelumab administered at 800 mg IV every two weeks in combination with axitinib, 5 mg PO BID.
Interventions:
  • Drug: Avelumab (MSB0010718C)
  • Drug: Axitinib (AG-013736)
Publications *Not Provided


*   Includes publications given by the data provider as well as publications
identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Recruitment Information
Recruitment Status  ICMJE Active, not recruiting
Actual Enrollment  ICMJE
 (submitted: July 26, 2019)
59
Original Estimated Enrollment  ICMJE
 (submitted: March 20, 2018)
80
Estimated Study Completion Date  ICMJE September 18, 2020
Estimated Primary Completion DateSeptember 18, 2020   (Final data collection date for primary outcome measure)
Eligibility Criteria  ICMJE

Inclusion Criteria:

  • Non-small cell lung cancer (NSCLC) Cohort: Histologically or cytologically confirmed diagnosis of NSCLC that is locally advanced or metastatic; No activating EGFR mutations, ALK or ROS1 translocations/rearrangements where testing is standard of care; received at least 1 prior platinum?based chemotherapy regimen for locally advanced or metastatic NSCLC; No more than 2 prior lines of systemic therapy for locally advanced or metastatic disease (If disease progression occurred during or within 6 months after neoadjuvant/adjuvant chemotherapy or radiotherapy?chemotherapy, the regimen is counted as 1 prior treatment regimen towards the allowed limit of prior treatment regimens); Checkpoint inhibitor naïve.
  • Urothelial Cancer (UC) Cohort: Histologically or cytologically confirmed diagnosis of transitional cell carcinoma (TCC) of the urothelium (if mixed, more than 50% TCC component) including bladder, urethra, ureters, or renal pelvis that is locally advanced or metastatic; No prior systemic treatment for locally advanced or metastatic disease; Prior neoadjuvant or adjuvant therapy is permitted if disease progression occurred >12 months after the completion of therapy; Checkpoint inhibitor naïve; Ineligible for receiving cisplatin?containing front?line chemotherapy based at least one of the following criteria: ECOG performance status (PS) 2; Renal dysfunction (defined as creatinine?clearance <60 ml/min); Grade 2 peripheral neuropathy; Grade 2 hearing loss (hearing loss measured by audiometry of 25 decibels at two contiguous frequencies).
  • At least 1 measurable lesion by RECIST v1.1 not previously irradiated.
  • Availability of an archival FFPE tumor tissue block from primary diagnosis specimen or metastatic specimen or 15 unstained slides (10 minimum). If an archived sample is not available, a fresh tumor biopsy must be performed.
  • Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1. For UC patients, ECOG performance 2 is permitted (cisplatin ineligibility criterion)

Exclusion Criteria:

  • Prior immunotherapy with an anti?PD?1, anti?PD?L1, anti?PD?L2, anti?CD137, anti?OX?40, anti?GITR, anti?LAG?3, anti?TIM?3 or anti?CTLA?4 antibody (including ipilimumab).
  • Newly diagnosed brain metastases or known symptomatic brain metastases requiring steroids.
  • Radiologically documented evidence of major blood vessel invasion or encasement by cancer or intratumor cavitation, regardless of tumor histology.
  • Active autoimmune disease (that might deteriorate when receiving an immunostimulatory agent).
  • Current use of immunosuppressive medication (except for those listed in protocol).
  • Known prior severe hypersensitivity to the investigational products /monoclonal antibodies.
  • Known history of immune?mediated colitis, inflammatory bowel disease, immune?mediated pneumonitis, pulmonary fibrosis.
  • NCI CTCAE Grade 3 hemorrhage within 28 days prior to study enrollment.
Sex/Gender  ICMJE
Sexes Eligible for Study:All
Ages  ICMJE 18 Years and older   (Adult, Older Adult)
Accepts Healthy Volunteers  ICMJE No
Contacts  ICMJE Contact information is only displayed when the study is recruiting subjects
Listed Location Countries  ICMJE Hungary,   Italy,   Korea, Republic of,   Poland,   Russian Federation,   Spain,   Taiwan,   United States
Removed Location Countries  
 
Administrative Information
NCT Number  ICMJE NCT03472560
Other Study ID Numbers  ICMJE B9991027
2017-004345-24 ( EudraCT Number )
AVE/ AXI COMBO UC ( Other Identifier: Alias Study Number )
AVE/AXI COMBO UC/NSCLC ( Other Identifier: Alias Study Number )
Has Data Monitoring CommitteeNo
U.S. FDA-regulated Product
Studies a U.S. FDA-regulated Drug Product:Yes
Studies a U.S. FDA-regulated Device Product:No
IPD Sharing Statement  ICMJE
Plan to Share IPD:Yes
Plan Description:Pfizer will provide access to individual de-identified participant data and related study documents (e.g. protocol, Statistical Analysis Plan (SAP), Clinical Study Report (CSR)) upon request from qualified researchers, and subject to certain criteria, conditions, and exceptions. Further details on Pfizer's data sharing criteria and process for requesting access can be found at: https://www.pfizer.com/science/clinical_trials/trial_data_and_results/da....
URL:https://www.pfizer.com/science/clinical_trials/trial_data_and_results/da...
Responsible PartyPfizer
Study Sponsor  ICMJE Pfizer
Collaborators  ICMJE Not Provided
Investigators  ICMJE
Study Director:Pfizer CT.gov Call CenterPfizer
PRS AccountPfizer
Verification DateJuly 2019

ICMJE     Data element required by the

International Committee of Medical Journal Editors
and the
World Health Organization ICTRP

FOR MORE INFORMATION

Contact a representative by phone, email, or visiting the study website. Please see the references below:

BY PHONE

Pfizer Clinical Trials Contact Center

1-800-718-1021

BY EMAIL

Contact

[email protected]

Call Now